Head-To-Head Contrast: Argos Therapeutics (ARGS) vs. Myovant Sciences (MYOV)

Argos Therapeutics (NASDAQ: ARGS) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.


This table compares Argos Therapeutics and Myovant Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -13,750.64% -1,532.49% -120.95%
Myovant Sciences N/A -53.75% -48.90%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Argos Therapeutics and Myovant Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 3 0 0 2.00
Myovant Sciences 0 0 4 0 3.00

Argos Therapeutics presently has a consensus price target of $1.20, suggesting a potential upside of 700.00%. Myovant Sciences has a consensus price target of $22.50, suggesting a potential upside of 87.66%. Given Argos Therapeutics’ higher probable upside, equities research analysts clearly believe Argos Therapeutics is more favorable than Myovant Sciences.

Valuation & Earnings

This table compares Argos Therapeutics and Myovant Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $950,000.00 13.88 -$53.02 million ($1.26) -0.12
Myovant Sciences N/A N/A -$83.44 million ($1.41) -8.50

Argos Therapeutics has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

18.4% of Argos Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Myovant Sciences shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Comparatively, 2.8% of Myovant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Myovant Sciences beats Argos Therapeutics on 6 of the 11 factors compared between the two stocks.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit